These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 21736857)

  • 1. Cost-effectiveness of etanercept treatment in early active rheumatoid arthritis followed by dose adjustment.
    Kobelt G; Lekander I; Lang A; Raffeiner B; Botsios C; Geborek P
    Int J Technol Assess Health Care; 2011 Jul; 27(3):193-200. PubMed ID: 21736857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treating to target with etanercept in rheumatoid arthritis: cost-effectiveness of dose reductions when remission is achieved.
    Kobelt G
    Value Health; 2014 Jul; 17(5):537-44. PubMed ID: 25128046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost effectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial.
    Kobelt G; Lindgren P; Singh A; Klareskog L
    Ann Rheum Dis; 2005 Aug; 64(8):1174-9. PubMed ID: 15708879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An economic approach to health care.
    Homik JE; Suarez-Almazor M
    Best Pract Res Clin Rheumatol; 2004 Apr; 18(2):203-18. PubMed ID: 15121040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A cost effectiveness analysis of treatment options for methotrexate-naive rheumatoid arthritis.
    Choi HK; Seeger JD; Kuntz KM
    J Rheumatol; 2002 Jun; 29(6):1156-65. PubMed ID: 12064828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment strategies aiming at remission in early rheumatoid arthritis patients: starting with methotrexate monotherapy is cost-effective.
    Schipper LG; Kievit W; den Broeder AA; van der Laar MA; Adang EM; Fransen J; van Riel PL
    Rheumatology (Oxford); 2011 Jul; 50(7):1320-30. PubMed ID: 21371999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic evaluation of etanercept in the management of chronic plaque psoriasis.
    Lloyd A; Reeves P; Conway P; Reynolds A; Baxter G
    Br J Dermatol; 2009 Feb; 160(2):380-6. PubMed ID: 18808413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modeling and cost-effectiveness analysis of etanercept in adults with rheumatoid arthritis in Japan: a preliminary analysis.
    Tanno M; Nakamura I; Ito K; Tanaka H; Ohta H; Kobayashi M; Tachihara A; Nagashima M; Yoshino S; Nakajima A
    Mod Rheumatol; 2006; 16(2):77-84. PubMed ID: 16633926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modeling the cost-effectiveness of treatment of rheumatoid arthritis with rituximab using registry data from Southern Sweden.
    Lindgren P; Geborek P; Kobelt G
    Int J Technol Assess Health Care; 2009 Apr; 25(2):181-9. PubMed ID: 19331709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The economic burden of biological therapy in rheumatoid arthritis in clinical practice: cost-effectiveness analysis of sub-cutaneous anti-TNFalpha treatment in Italian patients.
    Benucci M; Li Gobbi F; Sabadini L; Saviola G; Baiardi P; Manfredi M
    Int J Immunopathol Pharmacol; 2009; 22(4):1147-52. PubMed ID: 20074482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estimating the cost and health status consequences of treatment with TNF antagonists in patients with psoriatic arthritis.
    Bansback NJ; Ara R; Barkham N; Brennan A; Fraser AD; Conway P; Reynolds A; Emery P
    Rheumatology (Oxford); 2006 Aug; 45(8):1029-38. PubMed ID: 16782734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden.
    Bansback NJ; Brennan A; Ghatnekar O
    Ann Rheum Dis; 2005 Jul; 64(7):995-1002. PubMed ID: 15550533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of real-world infliximab use in patients with rheumatoid arthritis in Sweden.
    Lekander I; Borgström F; Svarvar P; Ljung T; Carli C; van Vollenhoven RF
    Int J Technol Assess Health Care; 2010 Jan; 26(1):54-61. PubMed ID: 20059781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of adalimumab, etanercept, and tocilizumab as first-line treatments for moderate-to-severe rheumatoid arthritis.
    Soini EJ; Hallinen TA; Puolakka K; Vihervaara V; Kauppi MJ
    J Med Econ; 2012; 15(2):340-51. PubMed ID: 22168785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison between integrating clinical practice setting and randomized controlled trial setting into economic evaluation models of therapeutics.
    Farahani P; Levine M; Goeree R
    J Eval Clin Pract; 2006 Aug; 12(4):463-70. PubMed ID: 16907691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost utility of tumour necrosis factor-α inhibitors for rheumatoid arthritis: an application of Bayesian methods for evidence synthesis in a Markov model.
    Nguyen CM; Bounthavong M; Mendes MA; Christopher ML; Tran JN; Kazerooni R; Morreale AP
    Pharmacoeconomics; 2012 Jul; 30(7):575-93. PubMed ID: 22640174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to methotrexate.
    Vera-Llonch M; Massarotti E; Wolfe F; Shadick N; Westhovens R; Sofrygin O; Maclean R; Yuan Y; Oster G
    Rheumatology (Oxford); 2008 Apr; 47(4):535-41. PubMed ID: 18356179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis.
    Finckh A; Bansback N; Marra CA; Anis AH; Michaud K; Lubin S; White M; Sizto S; Liang MH
    Ann Intern Med; 2009 Nov; 151(9):612-21. PubMed ID: 19884622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness analysis of rituximab treatment in patients in Germany with rheumatoid arthritis after etanercept-failure.
    Merkesdal S; Kirchhoff T; Wolka D; Ladinek G; Kielhorn A; Rubbert-Roth A
    Eur J Health Econ; 2010 Feb; 11(1):95-104. PubMed ID: 19967426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A cost-effectiveness analysis of treatment options for patients with methotrexate-resistant rheumatoid arthritis.
    Choi HK; Seeger JD; Kuntz KM
    Arthritis Rheum; 2000 Oct; 43(10):2316-27. PubMed ID: 11037892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.